Control patients without improvement will cross over to receive remestemcel-L at 3 months and may be retreated at 6 months. All patients will be followed for two years post initial treatment.
Yes Wilbs, the trials involving Rem-l for Chrons and Ulcerative Colitis have crossover of controls.
Given that there is pathological similarities with inflammation in the gastro intestinal tract and other organs, I am of the view that the efficacy signal stated by P Krause in aGvHD and early Amy Lightner updates at Ecco of early Rem-l success, plus the new complete healing results I recently posted for msc's , will culminate in IBD being partnered and rather quickly.
All these early trials with a primary endpoint of safety and feasibility are CURING the patients.
Waiting sucks
Viva la Revolucion
El Reg
Control patients without improvement will cross over to receive...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.105(8.43%) |
Mkt cap ! $1.541B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $16.46M | 12.22M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 59739 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |